^
    Back
    Association details:
    Biomarker:DEDD overexpression
    Cancer:Triple Negative Breast Cancer
    Drug Class:EGFR inhibitor +
    CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Research
    Title:

    Abstract 4841: Functional genome-wide screening identifies triple-negative breast cancer cell cycle-dependent vulnerability driven by genomic gain of death effector domain-containing protein

    Excerpt:
    ...we found TNBC with DEDD overexpression to be sensitive to a combination of CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo, independent of Rb status.
    DOI:
    10.1158/1538-7445.AM2020-4841